Revelation Biosciences Boosts Funding and Growth with Strategic Warrant Exercise for Immunity Therapies

Revelation Biosciences Advances Immunity-Based Therapeutics with Strategic Warrant Exercise

Revelation Biosciences, Inc., a clinical-stage life sciences company, focuses on harnessing trained immunity as a therapeutic approach for various diseases. In a significant development, the company announces a definitive agreement for the immediate exercise of certain outstanding warrants, allowing the purchase of up to 4,064,040 shares of common stock at a price of $1.00 per share. Originally issued in August 2024, these warrants represent a strategic move to secure immediate funding that supports the company’s ongoing research and development initiatives. The transaction, set to close around December 3, 2024, is expected to enhance Revelation's financial position, enabling it to further advance its innovative therapies.

The agreement involves a cash exercise for the warrants, leading to the issuance of new Class F and Class G warrants in a private placement. This arrangement allows current warrant holders to exchange their existing warrants for new ones, which will have different exercise terms. The Class F warrants will be valid for two years after stockholder approval, while the Class G warrants will have a five-year term, both priced at $1.00 per share. This strategic structure not only incentivizes current investors but also lays the groundwork for future financing opportunities. The immediate cash influx is critical for Revelation as it seeks to advance its pipeline of products aimed at leveraging trained immunity, a burgeoning area in immunology that focuses on enhancing the body’s innate immune response.

Furthermore, Revelation Biosciences is committed to transparency and regulatory compliance, pledging to file a resale registration statement with the SEC within 20 days of the closing. This move is crucial for facilitating the resale of shares related to the new warrants, thereby promoting market liquidity and investor confidence. As the company continues to innovate in the field of trained immunity, these developments signal a proactive approach to funding and growth, positioning Revelation Biosciences as a key player in the life sciences sector.

In addition to this significant financial maneuver, Revelation maintains its focus on clinical advancements. The company is actively engaged in research aimed at exploring the potential of trained immunity to provide new treatment avenues for diseases that currently lack effective therapies. As the biotechnology landscape evolves, Revelation’s commitment to leveraging its unique approach could yield significant benefits for patients and investors alike, enhancing its reputation as a forward-thinking entity in the life sciences industry.